MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.43 -0.69

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.82

Max

27.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+98.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-25

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

196M

1.7B

Ankstesnė atidarymo kaina

28.12

Ankstesnė uždarymo kaina

27.43

Naujienos nuotaikos

By Acuity

50%

50%

190 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-08 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

2026-01-08 21:39; UTC

Įsigijimai, susijungimai, perėmimai

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

2026-01-08 20:54; UTC

Įsigijimai, susijungimai, perėmimai

Glencore, Rio Tinto Restart Merger Talks -- Update

2026-01-08 20:44; UTC

Įsigijimai, susijungimai, perėmimai

Glencore, Rio Tinto Restart Merger Talks

2026-01-08 17:05; UTC

Įsigijimai, susijungimai, perėmimai

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

2026-01-08 16:43; UTC

Pagrindinės rinkos jėgos

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

2026-01-08 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-08 23:37; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

2026-01-08 22:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-08 22:42; UTC

Rinkos pokalbiai

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

2026-01-08 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

2026-01-08 21:53; UTC

Uždarbis

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

2026-01-08 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-08 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-08 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

2026-01-08 21:09; UTC

Rinkos pokalbiai

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

2026-01-08 21:09; UTC

Įsigijimai, susijungimai, perėmimai

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

2026-01-08 20:21; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

2026-01-08 19:44; UTC

Rinkos pokalbiai

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

2026-01-08 18:50; UTC

Rinkos pokalbiai

Mexico's Industrial Production Seen Lower in November -- Market Talk

2026-01-08 17:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

2026-01-08 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-08 17:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-08 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-08 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-01-08 16:45; UTC

Rinkos pokalbiai

Goldman Lifts 1H LME Copper Forecast -- Market Talk

2026-01-08 16:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-08 16:03; UTC

Rinkos pokalbiai

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

2026-01-08 16:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

2026-01-08 15:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Defends Its Hostile Bid for Warner -- Update

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

98.13% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  98.13%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

190 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat